KRAS and non-small cell lung carcinoma: The estimated incidence for KRAS altered cancers in the US based on this prevalence data is highest in CRC with almost 75,000 cases followed by PDAC and non-squamous (non-Sq) NSCLC (>50,000 cases each; Fig. 1b and Supplemental Table 1).